iRhythm is executing a volume-led growth strategy, with revenue accelerating to 20.1% YoY in 2026Q2 and gross margin expanding to 72.8%. The company achieved its first profitable quarter in 2025Q4 (net income of $5.6M) and generated $37.5M in FCF in 2026Q2, signaling a potential inflection.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | $0.82+5204.0% vs $0.02 | $222M-0.3% vs $222M |
Q3 2026 Aug 6, 2026 | -$0.01+75.0% vs -$0.04 | $224M+2.2% vs $219M |
Q2 2026 Apr 30, 2026 | -$0.43+23.2% vs -$0.56 | $199M+2.7% vs $194M |
Q1 2026 Feb 19, 2026 | $0.17+750.0% vs $0.02 | $209M+3.5% vs $202M |
SAN FRANCISCO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company with a mission to create trusted solutions that detect, predict, and prevent disease, today announced that it will participate in the following investor conferences.
iRhythm Technologies NASDAQ: IRTC raised its 2026 revenue and profitability outlook after reporting third-quarter growth driven by its core Zio monitor business, even as demand for its Zio AT telemetry product fell short of expectations.
iRhythm Holdings, Inc. (IRTC) Q3 2026 Earnings Call Transcript
iRhythm Holdings, Inc. (IRTC) came out with quarterly earnings of $0.82 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to a loss of $0.06 per share a year ago.
Benchmark IRTC against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for iRhythm Technologies, Inc. (IRTC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $90.22 | $2.96B | -77.39 | 26.24% | -4.52% | -22.8% | — | |
| $126.56 | $4.3B | 42.23 | 7.57% | 5.68% | 6.02% | — | |
| $19.10 | $1.41B | 7.12 | 18.52% | 43.79% | 15.84% | — | |
| $211.88 | $58.38B | 50.76 | -10.91% | 5.66% | 3.67% | 1.96% | |
| $13.28 | $1.54B | -12.74 | 8.28% | -16.78% | -35.81% | — | |
| $101.80 | $130.7B | 25.01 | 8.43% | 13.93% | 10.51% | 2.78% |
iRhythm Technologies, Inc. (IRTC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
iRhythm Technologies, Inc. (IRTC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Aug 6, 2026·SEC
Aug 6, 2026·SEC
Get notified when IRTC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
iRhythm Technologies, Inc. (IRTC) stock FAQ — growth, dividends, profitability & financials explained
iRhythm Technologies, Inc. (IRTC) reported $854.0M in revenue over the trailing twelve months. Revenue was $747.1M in fiscal year 2025. That is 4762% more than the $15.4M of fiscal year 2013.
iRhythm Technologies, Inc. (IRTC) grew revenue by 21.6% over the trailing twelve months, compared with the twelve months before.
No. iRhythm Technologies, Inc. (IRTC) reported a net loss of $38.6M over the trailing twelve months.
iRhythm Technologies, Inc. (IRTC) had a return on equity (ROE) of -22.8% over the trailing twelve months. A negative ROE means the company lost money over the period.
iRhythm Technologies, Inc. (IRTC) generated $7.4M in free cash flow over the trailing twelve months.
